AAFPRS President Addresses Concerns About Moderna COVID-19 Vaccine
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
The expanded indication is based on clinical data showing high responder rates and results lasting up to 18 months, with no serious adverse events reported.